Search research articles
Contact Us
Filters
Showing results (201-210 of 232) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Biomarker Research
|
March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
Era L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
Jason E Farrar, Jenny L Smith, Megan Othus, et al.
Cancer Cell
|
August 20, 2021
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang, Sixue Liu, Zhentao Yang, et al.
Blood Advances
|
June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
Anna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
Haematologica
|
November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
Anna B Halpern, Megan Othus, Emily M Huebner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
British Journal of Haematology
|
July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
Fabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 232) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 14, 2022
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Biomarker Research
|
March 17, 2023
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
Era L Pogosova-Agadjanyan, Xing Hua, Megan Othus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2023
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia
Jason E Farrar, Jenny L Smith, Megan Othus, et al.
Cancer Cell
|
August 20, 2021
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy
Yujue Wang, Sixue Liu, Zhentao Yang, et al.
Blood Advances
|
June 20, 2023
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML
Anna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
Haematologica
|
November 10, 2018
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
Anna B Halpern, Megan Othus, Emily M Huebner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 24, 2020
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Sandip P Patel, Megan Othus, Young Kwang Chae, et al.
British Journal of Haematology
|
July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
Fabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Page
of 24